Schizophrenia Spectrum

Study Notes

1. EPIDEMIOLOGY

1.1 Prevalence and Incidence

Swipe to compare →

1.2 Age of Onset

• Mean onset: Males ~21 years, Females ~27 years
• The estrogen hypothesis explains the later female onset and second perimenopausal peak (loss of protective dopamine-modulating effects of estrogen)
• Very early onset (<13 years) = childhood-onset schizophrenia (rare, poor prognosis)
• Late-onset (>40 years) = more paranoid, better premorbid, more female, better outcome

1.3 Sex Differences

1.4 Urban-Rural and Migration

• Urban birth effect: 2-3x higher incidence in urban settings (social drift + social causation)
• Migration: 2-3x increased risk, especially in ethnic minorities (social defeat hypothesis)
• Season of birth: Slight excess of winter/spring births in Northern Hemisphere (~5-8% excess)
• Latitude effect: Higher incidence at higher latitudes (vitamin D hypothesis)

2. CLINICAL FEATURES

2.1 Positive Symptoms

Hallucinations

Key auditory hallucination features in schizophrenia:

• Third-person voices (two or more voices arguing about the patient), Schneider's FRS
• Running commentary (voice describing actions as they happen), Schneider's FRS
• Command hallucinations, assess always for dangerousness
• Thought echo (echo de la pensee), hearing own thoughts spoken aloud
• Location: typically perceived as external, in clear consciousness

Delusions

Passivity phenomena (Schneider's FRS):

• Thought insertion, alien thoughts placed into mind
• Thought withdrawal, thoughts removed from mind
• Thought broadcasting, thoughts transmitted to others
• Made feelings/impulses/actions, will is replaced by external agency
• Somatic passivity, bodily sensations imposed from outside

Formal Thought Disorder (FTD)

Disorganized Behavior

• Unpredictable agitation
• Inappropriate sexual behavior
• Bizarre dress/appearance
• Disorganized goal-directed activity
• Catatonic features (see Section 5)

2.2 Negative Symptoms

Andreasen's Classification (Scale for Assessment of Negative Symptoms, SANS)

Primary vs Secondary Negative Symptoms:

Deficit syndrome (Carpenter & Kirkpatrick): Primary, enduring negative symptoms present during and between psychotic episodes. ~15-25% of schizophrenia cases. Associated with worse cognitive impairment and poorer outcome.

2.3 Cognitive Symptoms

Often the most disabling domain but historically overlooked.

• Present in 80% of patients
• Often predate psychosis onset by years
• Best predictor of functional outcome (more than positive or negative symptoms)
• Largely unresponsive to antipsychotics
• MATRICS Consensus Cognitive Battery (MCCB), 7 domains, gold standard assessment

2.4 Schneider's First Rank Symptoms (FRS)

Kurt Schneider (1959), proposed these as "first rank" because of their diagnostic weighting, NOT because of frequency or severity.

Second Rank Symptoms:

• Other hallucinations (visual, tactile, olfactory)
• Perplexity
• Depressive and euphoric mood changes
• Emotional blunting
• Delusional intuition (sudden delusional idea, not based on perception)

Current Status of FRS:

• NOT pathognomonic for schizophrenia (found in 10-20% of bipolar, temporal lobe epilepsy, substance-induced psychosis)
• Removed as a special criterion in DSM-5 (previously, one FRS alone was sufficient in DSM-IV)
• ICD-11 also does not give FRS special diagnostic weight
• Useful clinically for phenomenological description
• Cross-cultural validity questioned (different rates across cultures)
• Still frequently asked in exams despite diminished diagnostic status

3. CLASSIFICATION

3.1 Historical Evolution

Bleuler's 4 A's (Fundamental Symptoms):

1. Association disturbance (loosening), considered most fundamental
2. Affect disturbance (inappropriate, blunted)
3. Ambivalence (coexistence of opposite feelings)
4. Autism (withdrawal into inner world)

Accessory symptoms (not fundamental): Hallucinations, delusions

3.2 ICD-11 vs DSM-5

Key points for exam:

• ICD-11 requires only 1 month of symptoms; DSM-5 requires 6 months total
• Both dropped subtypes (paranoid, hebephrenic, etc.)
• ICD-11 uses symptom qualifiers for dimensional profiling
• DSM-5 requires functional impairment; ICD-11 does not mandate it
• Both removed special status of Schneider's FRS

3.3 Diagnostic Criteria: DSM-5

Criterion A (at least 2, for significant portion of 1 month, at least one must be 1, 2, or 3):

1. Delusions
2. Hallucinations
3. Disorganized speech
4. Grossly disorganized or catatonic behavior
5. Negative symptoms

Criterion B: Social/occupational dysfunction

Criterion C: Duration of at least 6 months (including prodrome/residual)

Criterion D: Schizoaffective and mood disorder excluded

Criterion E: Not due to substance/medical condition

Criterion F: If ASD or childhood communication disorder present, diagnosis only if prominent delusions/hallucinations for at least 1 month

4. SUBTYPES (HISTORICAL)

Why they were dropped: Low diagnostic reliability, limited clinical utility, patients shifted between subtypes over time, did not predict treatment response or outcome.

5. CATATONIA

5.1 Clinical Features

Bush-Francis Catatonia Rating Scale (BFCRS), 23 items, most widely used.

Screening items (14 items):

Additional features:

• Catalepsy, maintaining an externally imposed posture
• Ambitendency, appearing "stuck" in indecisive, hesitant movements
• Automatic obedience, exaggerated cooperation
• Mitgehen, arm raised to light pressure despite instruction to resist
• Gegenhalten, resistance equal to force of stimulus
• Grasp reflex, grasps examiner's hand despite instruction not to

5.2 Catatonia in Current Classification

5.3 Medical Causes of Catatonia

• Neurological: Encephalitis (especially anti-NMDA receptor), stroke, seizures, brain tumors
• Metabolic: Hepatic encephalopathy, diabetic ketoacidosis, hypercalcemia, hyponatremia
• Autoimmune: SLE, anti-NMDA receptor encephalitis
• Endocrine: Thyroid storm, Addisonian crisis
• Drug-induced: NMS (consider as malignant catatonia), serotonin syndrome, phencyclidine
• Infectious: HIV, neurosyphilis

5.4 Lorazepam Challenge Test

5.5 ECT for Catatonia

Indications for ECT:

• Malignant catatonia (fever, autonomic instability, elevated CK)
• Failed lorazepam challenge or inadequate response to benzodiazepines
• Life-threatening complications (dehydration, DVT, PE, pressure sores)
• Lethal catatonia / NMS unresponsive to medical management

Protocol:

• Bilateral ECT preferred
• Daily or alternate day in acute malignant catatonia
• Typically 6-10 sessions
• Response rate: 80-90% in catatonia (highest of any ECT indication)

6. COURSE AND OUTCOME

6.1 Course Patterns

General trajectory:

• Prodromal phase (months to years): Social withdrawal, decline in functioning, attenuated psychotic symptoms
• Active phase: Frank psychotic symptoms
• Residual phase: Negative symptoms predominate, some positive symptoms attenuated
• ~80% relapse within 5 years of first episode if untreated
• ~30% have a relatively good outcome, ~30% intermediate, ~30% poor, ~10% dead by suicide

6.2 Prognostic Factors

WHO DOSMeD study finding: Better outcome in developing countries (India, Nigeria, Colombia) compared to developed countries, possibly due to extended family support, less expressed emotion, reintegration into community roles.

6.3 Andreasen's Remission Criteria (2005)

Requires ALL of the following for at least 6 months:

• Severity of ≤ mild (3 on PANSS 7-point scale) on EACH of these 8 items:
• Delusions (P1)
• Unusual thought content (G9)
• Hallucinatory behavior (P3)
• Conceptual disorganization (P2)
• Mannerisms/posturing (G5)
• Blunted affect (N1)
• Social withdrawal (N4)
• Lack of spontaneity (N6)

Key points:

• Both symptom severity AND time criteria must be met
• Remission ≠ recovery (recovery also requires functional improvement)
• Approximately 20-30% of patients meet remission criteria with treatment

6.4 Mortality and Suicide

• Life expectancy reduced by 15-20 years
• Suicide: ~5% lifetime risk (previously cited as 10%, revised downward)
• Highest risk: Young males, early illness, depression, previous attempts, substance use, high IQ (awareness of losses)
• Cardiovascular disease is the leading cause of excess mortality
• SMR (Standardized Mortality Ratio): 2-3x general population

7. ETIOLOGY

7.1 Dopamine Hypothesis

Evolution:

Four dopamine pathways:

7.2 Glutamate Hypothesis

• NMDA receptor hypofunction, PCP and ketamine (NMDA antagonists) produce positive AND negative symptoms and cognitive deficits
• More comprehensive than dopamine hypothesis (explains negative/cognitive symptoms)
• NMDA hypofunction on GABAergic interneurons → disinhibition of glutamate neurons → downstream dopamine dysregulation
• Glycine site modulators (D-serine, sarcosine), modest benefits in trials
• Links to neurodevelopmental model (NMDA receptors crucial for synaptic plasticity)

7.3 Serotonin Hypothesis

• 5-HT2A receptor involvement (LSD, a 5-HT2A agonist, causes hallucinations)
• SGAs have high 5-HT2A/D2 affinity ratio
• Pimavanserin (5-HT2A inverse agonist) effective in Parkinson's psychosis
• Serotonin modulates dopamine release in mesolimbic and mesocortical pathways

7.4 Neurodevelopmental Model

Two-hit model (Keshavan):

• First hit: Early neurodevelopmental insult (genetic + prenatal)
• Second hit: Adolescent/early adult triggers (stress, cannabis, excessive synaptic pruning)
• Disease manifests when second hit occurs on vulnerable substrate

7.5 Genetics

7.6 Cannabis and Psychosis

• Cannabis use in adolescence → 2-6x increased risk of schizophrenia
• Dose-response relationship (earlier use + higher potency = greater risk)
• THC → dopamine release in mesolimbic pathway
• CBD may have antipsychotic properties
• Gene-environment interaction: COMT Val/Val genotype + cannabis = highest risk
• Does NOT cause schizophrenia alone, requires genetic vulnerability

7.7 Other Etiological Factors

• Expressed emotion (EE): High EE (criticism, hostility, emotional over-involvement) → higher relapse rates (Vaughn & Leff, 1976)
• Social isolation/defeat: Social exclusion activates mesolimbic dopamine
• Childhood adversity: 2-3x increased risk with childhood trauma
• Vitamin D deficiency: Neonatal vitamin D levels inversely correlated with risk

8. MANAGEMENT

8.1 Antipsychotics: Overview

Mechanism: ALL effective antipsychotics block D2 receptors. The therapeutic window for D2 occupancy is 65-80%.

8.2 First-Generation Antipsychotics (FGA / "Typical")

FGA Side Effects by Receptor:

Extrapyramidal Symptoms (EPS), Timeline:

8.3 Second-Generation Antipsychotics (SGA / "Atypical")

Why "atypical"?

• Lower EPS risk at therapeutic doses
• 5-HT2A/D2 affinity ratio > 1 (Meltzer's hypothesis)
• Some efficacy for negative symptoms (debated)
• Fast dissociation from D2 receptor (Kapur's hypothesis, applies to quetiapine, clozapine)

8.4 Newer Antipsychotics

8.5 Long-Acting Injectables (LAI)

8.6 Metabolic Monitoring

All patients on antipsychotics should have baseline and ongoing monitoring:

Metabolic Syndrome (ATP III criteria, any 3 of 5):

Metabolic risk ranking (highest to lowest):

Clozapine = Olanzapine >> Quetiapine = Risperidone > Aripiprazole = Ziprasidone = Lurasidone

9. TREATMENT-RESISTANT SCHIZOPHRENIA (TRS)

9.1 Definition

International consensus (TRRIP Working Group, Howes et al., 2017):

• Failure of at least 2 adequate antipsychotic trials
• Each trial: adequate dose (equivalent to 600 mg/day chlorpromazine), adequate duration (at least 6 weeks, ideally 6-8 weeks at optimal dose), adequate adherence confirmed
• At least 1 trial should be with an SGA
• Persistent moderate-severe positive symptoms despite treatment
• Significant functional impairment

Prevalence: ~30% of schizophrenia patients (one-third of all cases)

Pseudo-resistance (rule out first):

• Non-adherence (most common cause)
• Inadequate dose or duration
• Substance use (especially cannabis, stimulants)
• Pharmacokinetic factors (rapid metabolizers, check CYP1A2 for clozapine, smoking)
• Comorbid conditions (depression, OCD)

9.2 Clozapine: The Gold Standard for TRS

Evidence base:

• Kane et al. (1988), landmark trial demonstrating superiority over chlorpromazine in TRS
• Only antipsychotic with proven superiority in TRS
• Also reduces suicidality (InterSePT trial, only FDA-approved indication for suicide reduction)
• Effective for aggression and violence in schizophrenia

Initiation Protocol

Therapeutic plasma level: 350-600 ng/mL (trough level, 12 hours post-dose)

Monitoring Protocol

Stopping rules for neutropenia:

Side Effects

Common (>10%):

Less common (1-10%):

Rare but serious (<1%):

Drug Interactions

9.3 Augmentation Strategies (When Clozapine Alone Fails)

Evidence-based (some level of support):

Ultra-treatment resistance: Failed adequate clozapine trial (plasma level >350 ng/mL for 8+ weeks) + augmentation attempts. Consider: clozapine + ECT, clozapine + amisulpride, clozapine + aripiprazole.

10. PSYCHOSOCIAL MANAGEMENT

10.1 Evidence-Based Psychosocial Interventions

10.2 Family Therapy in Schizophrenia

Rationale: High Expressed Emotion (EE) in family → 2-3x higher relapse rate (Vaughn & Leff, 1976).

Components of EE:

1. Critical comments
2. Hostility
3. Emotional over-involvement

Family intervention models:

Evidence:

• Reduces relapse by 20-50% when combined with medication
• NNT ~6-7 (for preventing one relapse over 12 months)
• Should be offered to ALL patients living with or in close contact with family
• Minimum 10 sessions over 3+ months
• Single family > multiple family (for relapse prevention)

10.3 Rehabilitation

Principles:

• Recovery-oriented (focus on strengths, not deficits)
• Person-centered goals
• Graded, stepwise approach
• Community integration as ultimate goal

Components:

• Life skills training (cooking, budgeting, hygiene, transport)
• Vocational rehabilitation (sheltered workshops → supported employment → competitive employment)
• Supported housing (group homes → independent living with support)
• Peer support programs
• Relapse prevention planning (early warning signs identification, crisis plan)

10.4 Prodromal Phase Interventions

At-Risk Mental State (ARMS) / Ultra-High Risk (UHR):

Interventions for prodromal phase:

• CBT, strongest evidence (reduces transition to psychosis)
• Omega-3 fatty acids, early promising data (Amminger et al., 2010); later trial (NEURAPRO) negative
• Low-dose antipsychotics, effective but ethical concerns (treating people who may never develop psychosis; side effects)
• Stress management, social support, substance use reduction
• Staged treatment, begin with benign interventions, escalate if needed

Conversion rate: ~30% of UHR individuals develop psychosis within 3 years

10.5 Compliance/Adherence

Non-adherence rates: 40-60% within first year; up to 75% within 2 years

Causes of poor compliance:

Strategies to improve compliance:

• Long-acting injectables (LAIs)
• Psychoeducation (patient + family)
• Simplify regimen (once daily dosing, combination pills)
• Motivational interviewing
• Shared decision-making
• Digital adherence monitoring (e.g., Abilify MyCite, aripiprazole with ingestible sensor)
• Therapeutic alliance building
• Address side effects proactively
• Family involvement
• Community mental health teams / ACT

11. SPECIAL TOPICS

11.1 Schizoaffective Disorder

• Concurrent mood episode + schizophrenia Criterion A symptoms
• Key: Delusions/hallucinations for 2+ weeks in ABSENCE of mood episode (differentiates from mood disorder with psychotic features)
• Bipolar type vs Depressive type
• Treatment: Antipsychotic + mood stabilizer/antidepressant

11.2 Schizotypal Personality Disorder

• In ICD-11: classified under schizophrenia spectrum (not personality disorders)
• Features: Ideas of reference, magical thinking, unusual perceptual experiences, odd thinking/speech, suspiciousness, inappropriate affect, odd behavior/appearance, few close relationships, excessive social anxiety
• Does NOT meet full psychotic criteria

11.3 Brief Psychotic Disorder / Acute and Transient Psychotic Disorder

• Duration: >1 day but <1 month (DSM-5) / variable (ICD-11)
• Full return to premorbid functioning
• With/without marked stressor
• Good prognosis

11.4 Delusional Disorder

• Non-bizarre delusions for >1 month
• Criterion A for schizophrenia never met (except tactile/olfactory hallucinations related to delusional theme)
• Functioning not markedly impaired
• Subtypes: Erotomanic, Grandiose, Jealous, Persecutory, Somatic, Mixed, Unspecified

11.5 Substance-Induced Psychosis vs Schizophrenia

Quick-Reference Summary Tables

Key Numbers to Remember

Model Answers

Q1. Describe positive and negative symptoms of schizophrenia. Discuss management of negative symptoms. [10 marks]: LONG ESSAY CANDIDATE

Exam Strategy: This is a high-frequency question. Split 3+3+4 (positive, negative, management of negative). Use tables. The management section is what differentiates a good answer, most students only write about antipsychotics.

Answer:

Introduction (0.5 marks)

Schizophrenia is a chronic psychotic disorder with a heterogeneous symptom profile. Eugen Bleuler first distinguished fundamental from accessory symptoms. The modern positive-negative dichotomy was formalized by Crow (1980) and elaborated by Andreasen (1982).

A. Positive Symptoms (3 marks)

Positive symptoms represent an excess or distortion of normal functions. They are generally responsive to antipsychotic medication and fluctuate with illness course.

Swipe to compare →

Assessment: Scale for Assessment of Positive Symptoms (SAPS, Andreasen), PANSS positive subscale.

B. Negative Symptoms (3 marks)

Negative symptoms represent a diminution or loss of normal functions. They are the primary determinant of long-term functional outcome.

Andreasen's SANS classification (5 domains):

Critical distinction, Primary vs Secondary:

• Primary: Intrinsic to illness (deficit syndrome, Carpenter); poor treatment response
• Secondary: Due to medication (EPS, sedation), depression, positive symptoms (withdrawal due to paranoia), environmental deprivation
• Management hinges on this distinction, secondary causes must be identified and addressed first

C. Management of Negative Symptoms (4 marks)

Step 1: Address secondary causes

• Reduce/switch antipsychotic if EPS or sedation contributing
• Treat comorbid depression (add SSRI/SNRI)
• Address substance use
• Enhance environmental stimulation
• Assess medication adherence

Step 2: Pharmacological approaches

Step 3: Psychosocial interventions

Conclusion: Management of negative symptoms requires a systematic approach: first rule out secondary causes, then use pharmacological strategies (cariprazine as first choice if available), and combine with psychosocial interventions targeting specific functional deficits.

Cross-reference: D1 Sections 2.2, 8.3, 8.4, 10.1

Q2. Define treatment-resistant schizophrenia (TRS). Discuss management protocol: pharmacological and psychological. [3+7 = 10 marks], LONG ESSAY CANDIDATE

Exam Strategy: Definition is 3 marks, be precise, include TRRIP criteria. Management is 7 marks, structure as algorithm. Clozapine is the bulk. Don't forget augmentation and psychosocial.

Answer:

A. Definition of TRS (3 marks)

Treatment-resistant schizophrenia (TRS) is defined as persistent, moderate-to-severe psychotic symptoms despite adequate antipsychotic treatment.

TRRIP Working Group Criteria (Howes et al., 2017):

1. Failure of at least 2 adequate antipsychotic trials (at least 1 SGA)
2. Each trial at adequate dose (equivalent to ≥600 mg/day chlorpromazine)
3. Each trial for adequate duration (≥6 weeks at optimal dose)
4. Adequate adherence confirmed (plasma levels, LAI, supervised intake)
5. Persistent moderate-severe positive symptoms (PANSS total >80 or CGI-S ≥4)
6. Significant functional impairment

Prevalence: ~30% of schizophrenia patients

Pseudo-resistance must be excluded: non-adherence, inadequate dose/duration, substance use, rapid metabolism, comorbid conditions.

B. Management Protocol (7 marks)

Step 1: Confirm TRS diagnosis

• Review treatment history (doses, durations, adherence)
• Check plasma drug levels
• Screen for substance use (urine drug screen)
• Consider CYP genotyping if suspecting rapid metabolism
• Assess for comorbidities (depression, OCD, PTSD)

Step 2: Clozapine trial, Gold standard

Initiation:

• Start 12.5 mg OD or BD
• Increase by 25-50 mg/day over first week
• Increase by 50-100 mg/week from week 2
• Target dose: 300-450 mg/day (up to 900 mg/day)
• Target plasma level: >350 ng/mL (trough, 12h post-dose)

Monitoring:

• WBC/ANC: Weekly for 18 weeks → Biweekly for 34 weeks → Monthly thereafter
• Metabolic parameters: Weight, BMI, fasting glucose, lipids at baseline and 3-monthly
• Cardiac: ECG at baseline, troponin/CRP if fever or tachycardia in first month
• Seizure risk: Increases with dose; consider valproate prophylaxis if >600 mg/day

Adequate clozapine trial: Minimum 8 weeks at therapeutic plasma level (>350 ng/mL)

Step 3: Clozapine augmentation (if clozapine monotherapy fails)

Step 4: Experimental/emerging

• Transcranial direct current stimulation (tDCS), for persistent auditory hallucinations
• Repetitive transcranial magnetic stimulation (rTMS), left temporo-parietal for hallucinations
• Electroconvulsive therapy (ECT), as augmentation

Psychological interventions for TRS:

Algorithm summary:

Confirm TRS → Optimize current treatment → Start clozapine → Titrate to therapeutic level → Augment if needed (amisulpride/aripiprazole/ECT/lamotrigine) → Combine with psychosocial interventions throughout.

Cross-reference: D1 Sections 9.1-9.3, 10.1

Q3. Plan a clozapine trial. Discuss initiation, monitoring, and side effects (common, less common, rare). [10 marks]

Exam Strategy: Highly structured answer. Use tables for each section. This is a practical question, show you can actually do it. 3+3+4 split approximately.

Answer:

Introduction (0.5 marks)

Clozapine is the gold standard for treatment-resistant schizophrenia. It is the only antipsychotic with demonstrated superiority in TRS (Kane et al., 1988) and the only one approved for reducing suicidality (InterSePT trial).

A. Pre-initiation Assessment (1 mark)

• Confirm TRS (2 failed adequate antipsychotic trials)
• Baseline investigations: CBC with differential (WBC >3500, ANC >2000), metabolic panel (fasting glucose, lipids, HbA1c), LFT, RFT, ECG, weight/BMI/waist circumference, blood pressure
• Cardiac assessment: Baseline troponin, CRP (for myocarditis monitoring)
• Inform patient and family: Written consent, side effect education, importance of monitoring compliance
• Register with clozapine monitoring service (REMS in US; equivalent in India)
• Stop medications that lower WBC (e.g., carbamazepine, contraindicated)

B. Initiation Protocol (2 marks)

• Cross-taper previous antipsychotic over 1-2 weeks (do not abruptly stop)
• If patient smokes: will need higher doses (CYP1A2 induction)
• Divided dosing preferred initially (BD), can shift to mainly nocturnal once stable

C. Monitoring Protocol (3 marks)

D. Side Effects (4 marks)

Common (>10%):

Less common (1-10%):

Rare but serious (<1%):

Conclusion: Clozapine remains the most effective antipsychotic for TRS but requires meticulous initiation, systematic monitoring, and proactive side effect management to ensure safety.

Cross-reference: D1 Section 9.2

Q4. Describe the course and outcome of schizophrenia. [10 marks]

Exam Strategy: Cover phases, course patterns, outcome statistics, mortality. Use WHO studies data. 2+3+3+2 split.

Answer:

Introduction (1 mark)

Kraepelin originally described schizophrenia (dementia praecox) as having a uniformly deteriorating course. Modern longitudinal studies show a heterogeneous course with outcomes ranging from full recovery to chronic disability.

A. Phases of Illness (2 marks)

B. Course Patterns (3 marks)

Rule of thirds (approximate):

• ~30% have a good outcome (remission, functional recovery)
• ~30% have an intermediate outcome (partial improvement, some functional impairment)
• ~30% have a poor outcome (chronic symptoms, significant disability)
• ~10% die by suicide

Key longitudinal studies:

C. Outcome Domains (2 marks)

D. Mortality (2 marks)

• Life expectancy reduced by 15-20 years
• Suicide: ~5% lifetime risk; highest in young males, early illness, depression, substance use
• Natural causes: Cardiovascular disease is the leading cause of premature death (metabolic syndrome from antipsychotics + lifestyle factors + reduced healthcare access)
• SMR: 2-3x general population
• Mortality gap widening over time (general population health improving faster)

Conclusion: Schizophrenia has a heterogeneous course. While Kraepelin's view of inevitable deterioration is overly pessimistic, outcomes remain variable. Early intervention, sustained treatment, psychosocial rehabilitation, and metabolic monitoring are essential to optimize outcomes.

Cross-reference: D1 Section 6

Q5. Discuss prognostic factors and outcomes of schizophrenia. [10 marks]

Exam Strategy: Overlap with Q4. Emphasize prognostic factors (this is the focus). Table format is ideal. Add evidence base.

Answer:

Introduction (1 mark)

Prognosis in schizophrenia is determined by the interaction of illness characteristics, patient factors, treatment variables, and sociocultural context. Identifying prognostic factors guides treatment planning and helps set realistic expectations.

A. Good Prognostic Factors (3 marks)

B. Poor Prognostic Factors (3 marks)

C. Evidence for Key Prognostic Factors (2 marks)

D. Outcome Data (1 mark)

• Andreasen's remission: 20-30% achieve
• Functional recovery: 14-20%
• Competitive employment: 10-20%
• Suicide: ~5%
• Premature mortality from natural causes: 15-20 year life expectancy reduction

Cross-reference: D1 Section 6.2, Q4 above

Q6. Enumerate Schneider's first rank symptoms. Discuss their difference from second and third rank symptoms. Comment on their current status. [10 marks]

Exam Strategy: 4+3+3 split. Enumerate all FRS clearly. Second rank is less commonly asked, show depth. Current status = critical evaluation.

Answer:

Introduction (0.5 marks)

Kurt Schneider (1959) proposed certain symptoms as having special diagnostic importance for schizophrenia, terming them "first rank symptoms" (FRS). He emphasized their diagnostic utility, not their frequency or pathological significance.

A. First Rank Symptoms (4 marks)

Category 1: Auditory Hallucinations

Category 2: Passivity Experiences (made phenomena)

Category 3: Thought Interference

Category 4: Delusional Perception

Total: 11 first rank symptoms (some texts count slightly differently depending on grouping).

B. Second and Third Rank Symptoms (3 marks)

Second rank symptoms (less diagnostic specificity):

Difference between FRS and Second Rank:

Third rank is not a formal Schneiderian concept. Some texts use it informally to refer to non-specific symptoms such as disturbances in mood, psychomotor changes, and behavioral disturbances that can occur in multiple psychiatric conditions.

C. Current Status of FRS (3 marks)

Conclusion: While Schneider's FRS were historically central to schizophrenia diagnosis, modern classification systems have appropriately reduced their diagnostic privilege. They remain valuable as clinical descriptors and phenomenological markers but are neither specific to nor necessary for the diagnosis of schizophrenia.

Cross-reference: D1 Section 2.4

Q7. Discuss atypical antipsychotics. Why are they called "atypical"? Are they effective for negative symptoms? Discuss side effects. [10 marks]

Exam Strategy: 2+3+2+3 split. "Why atypical" is the conceptual hook. Negative symptom question requires nuance, don't just say "yes."

Answer:

A. Why "Atypical"? (2 marks)

The term "atypical" was introduced to distinguish second-generation antipsychotics (SGAs) from first-generation (FGA/typical) based on several properties:

Three hypotheses for "atypicality":

1. Meltzer's serotonin-dopamine hypothesis: 5-HT2A/D2 affinity ratio >1 → selective mesolimbic D2 blockade, preserving nigrostriatal pathway
2. Kapur's fast dissociation: Rapid D2 off-rate allows physiological dopamine surges to compete → less EPS (applies to clozapine, quetiapine)
3. Limbic selectivity: Preferential action on mesolimbic over nigrostriatal pathways

B. Individual Atypical Antipsychotics (3 marks)

C. Efficacy for Negative Symptoms (2 marks)

Nuanced answer required:

• SGAs are NOT consistently superior to FGAs for primary negative symptoms (CATIE trial showed no clear advantage)
• SGAs reduce secondary negative symptoms by causing fewer EPS and less sedation
• Specific exceptions with evidence for primary negative symptoms:
• Cariprazine: RCT evidence of superiority over risperidone for predominant negative symptoms (Nemeth et al., 2017)
• Amisulpride (low dose, 50-300 mg): Preferential presynaptic D2/D3 blockade → may enhance dopamine transmission
• Clozapine: Improves overall symptom burden including negative symptoms in TRS
• The "atypicals are better for negative symptoms" claim was largely a marketing narrative; rigorous evidence is limited
• Primary negative symptoms remain one of the greatest unmet needs in schizophrenia treatment

D. Side Effects (3 marks)

Cross-reference: D1 Sections 8.3-8.4, D4 Table 3

Q8. Critical evaluation of typical antipsychotics in current practice. [10 marks]

Exam Strategy: Balanced answer. Don't just list disadvantages, show you understand their ongoing role. CATIE and CUtLASS data are key.

Answer:

Introduction (1 mark)

First-generation antipsychotics (FGAs/typicals) were the cornerstone of schizophrenia treatment from chlorpromazine's introduction (1952) until SGAs emerged in the 1990s. Their role in current practice requires a balanced evaluation considering efficacy, safety, cost, and access.

A. Mechanism and Classification (1 mark)

• Primary mechanism: D2 receptor antagonism
• High potency (haloperidol, fluphenazine, pimozide): More EPS, less sedation/autonomic
• Low potency (chlorpromazine, thioridazine): Less EPS, more sedation/hypotension/anticholinergic

B. Arguments for Continued Use (3 marks)

C. Arguments Against / Limitations (3 marks)

D. Current Guidelines and Role (2 marks)

Appropriate current indications for FGAs:

1. Acute agitation/emergency (haloperidol IM/IV)
2. Resource-limited settings where SGAs are unavailable/unaffordable
3. Patients who have responded well to FGAs previously
4. LAI formulations when SGA LAIs unavailable
5. Specific conditions (pimozide for delusional disorder)
6. When SGA metabolic effects are a greater concern than EPS risk

Conclusion: FGAs remain relevant in current practice, particularly in emergency settings and resource-limited environments. The choice between FGA and SGA should be individualized, weighing metabolic risks (SGAs) against EPS/TD risks (FGAs), patient preference, cost, and available formulations.

Cross-reference: D1 Section 8.2

Q9. Discuss psychosocial treatment and rehabilitation in schizophrenia. [5+5 = 10 marks]

Exam Strategy: Split clearly: psychosocial treatments (5 marks) and rehabilitation (5 marks). Mention evidence base for each.

Answer:

A. Psychosocial Treatments (5 marks)

Rationale: Antipsychotics alone achieve symptom remission in only 20-30%; functional recovery requires psychosocial interventions targeting residual symptoms, cognitive deficits, social skills, and vocational functioning.

B. Rehabilitation (5 marks)

Philosophy: Recovery model, focuses on living a meaningful life with or without symptoms, rather than "cure."

Principles:

• Person-centered (individual goals, preferences, strengths)
• Community-based (least restrictive environment)
• Graded and stepwise
• Holistic (biological + psychological + social + occupational)
• Rights-based (UNCRPD, United Nations Convention on Rights of Persons with Disabilities)

Components:

Indian context:

• DMHP (District Mental Health Programme): Community mental health services
• PG exams, CIP Ranchi, LGBRIMH: National rehabilitation centers
• Day care centers: Increasingly available in urban India
• Family as primary caregiver: Critical role in Indian context
• RPWD Act 2016: Disability certification, reservation in employment/education
• Limited access to specialized psychosocial interventions in rural areas

Phases of rehabilitation:

Cross-reference: D1 Sections 10.1-10.3

Q10. Discuss the role of family therapy in schizophrenia. [10 marks]

Exam Strategy: Focused question. Cover rationale (EE research), models, evidence, practical components. Show clinical depth.

Answer:

Introduction (1 mark)

Family interventions in schizophrenia are among the most well-evidenced psychosocial treatments, consistently recommended by NICE, APA, and PORT guidelines. They address the family environment, which significantly impacts relapse rates and patient functioning.

A. Rationale, Expressed Emotion Research (2 marks)

Expressed Emotion (EE) concept developed by Brown, Birley, and Wing (1962); operationalized by Vaughn and Leff (1976).

Key findings:

• High EE households: 50-65% relapse at 9 months vs 15-25% in low EE (Vaughn & Leff, 1976)
• Effect is dose-dependent: more face-to-face contact with high-EE relative = higher relapse
• Effect is cross-culturally replicated (though baseline EE levels differ)
• EE is modifiable through intervention
• EE is NOT blame, it is an understandable response to a distressing illness

B. Models of Family Intervention (3 marks)

Common elements across effective models:

1. Psychoeducation about the illness
2. Communication skills enhancement
3. Problem-solving training
4. Emotional processing and support
5. Relapse prevention planning
6. Crisis intervention strategies

C. Evidence Base (2 marks)

Evidence summary:

• NNT to prevent one relapse: ~6-7
• Reduces hospitalization
• Improves medication adherence
• Improves patient social functioning
• Reduces family burden and distress
• Single-family format > multi-family for relapse prevention
• Multi-family format better for social network expansion

D. Practical Implementation (2 marks)

Session structure (typical):

• Duration: 10-20 sessions over 6-12 months
• Frequency: Fortnightly initially, then monthly
• Setting: Home-based preferred (more effective than clinic-based)
• Participants: Patient + key family members
• Therapist: Trained mental health professional (can be nurse or social worker with training)

Phase-wise approach:

Barriers in Indian context:

• Stigma around mental illness and family therapy
• Large joint families, who to include
• Patriarchal dynamics may complicate sessions
• Limited trained family therapists
• Transport and time constraints (especially rural)
• Cultural expectations of family obligation vs therapeutic boundaries

Conclusion: Family therapy is a first-line psychosocial intervention in schizophrenia with robust evidence for reducing relapse, improving adherence, and reducing family distress. It should be offered to all patients in contact with family, using a psychoeducational or behavioral model.

Cross-reference: D1 Section 10.2

Q11. Compare the ICD-10 and DSM-5 diagnosis of schizophrenia. How does the diagnosis differ? [10 marks]

Exam Strategy: Table-based answer. Note: question says ICD-10 not ICD-11, cover both ICD-10 and mention ICD-11 updates.

Answer:

Introduction (0.5 marks)

The diagnosis of schizophrenia has evolved across classification systems. Understanding differences between ICD-10 (still widely used in India) and DSM-5 is essential for clinical practice and exam purposes.

A. Comparison Table (6 marks)

B. Key Diagnostic Differences (2 marks)

C. ICD-11 Updates (1.5 marks)

ICD-11 (implemented 2022) brings significant changes that align more closely with DSM-5:

Conclusion: The key practical difference is duration (1 month vs 6 months). ICD-11 has modernized significantly, dropping subtypes and FRS privilege, but retains the shorter duration criterion. Clinicians should be familiar with both systems.

Cross-reference: D1 Section 3.2, D4 Table 1

Q12. What is metabolic syndrome? Discuss its relationship with antipsychotic drugs. [5+5 = 10 marks]

Exam Strategy: Clean split. Define metabolic syndrome (ATP III criteria) then link systematically to antipsychotics.

Answer:

A. Metabolic Syndrome (5 marks)

Definition: Metabolic syndrome is a cluster of interconnected metabolic abnormalities that increase the risk of cardiovascular disease (2x) and type 2 diabetes (5x).

Diagnostic Criteria (Modified ATP III/NCEP, 2005), any 3 of 5:

Other criteria systems: IDF (2005) requires central obesity + 2 others; WHO (1998) requires insulin resistance.

Pathophysiology: Insulin resistance is the central mechanism → hyperinsulinemia → dyslipidemia → hypertension → pro-inflammatory state → prothrombotic state → accelerated atherosclerosis.

Prevalence in schizophrenia: 30-40% (2-3x general population rate).

B. Relationship with Antipsychotic Drugs (5 marks)

Mechanisms of antipsychotic-induced metabolic syndrome:

Risk ranking by drug:

Weight gain data (mean at 10 weeks):

Management:

Special note on Cobenfy (xanomeline-trospium): First antipsychotic with NO D2 blockade → no metabolic syndrome, no EPS, no prolactin elevation. May represent paradigm shift in metabolic safety.

Cross-reference: D1 Section 8.6

Q13. Describe prodromal symptoms of schizophrenia. Discuss interventions in the prodromal phase. [10 marks]

Exam Strategy: 4+6 split. Describe prodrome thoroughly, then interventions with evidence.

Answer:

A. Prodromal Symptoms (4 marks)

Definition: The prodromal phase is the period between the first noticeable change from premorbid functioning and the onset of frank psychotic symptoms. Duration: months to years (mean 2-5 years).

Prodromal symptoms:

At-Risk Mental State (ARMS) / Ultra-High Risk (UHR) Criteria (Yung & McGorry, PACE criteria):

Conversion rate: ~30% of UHR individuals develop frank psychosis within 3 years (though rates declining in recent studies, possibly due to treatment effects or referral bias).

Assessment tools:

• CAARMS (Comprehensive Assessment of At-Risk Mental States)
• SIPS/SOPS (Structured Interview for Prodromal Syndromes)

B. Interventions in the Prodromal Phase (6 marks)

Philosophy: Staged treatment, begin with least harmful interventions; escalate if needed. Balance risk of transition to psychosis against risks of unnecessary treatment.

Current guidelines:

• NICE: CBT for all ARMS patients; do NOT use antipsychotics prophylactically
• APA: No specific guidelines for prodromal phase
• International Early Psychosis Association: Staged approach with regular monitoring

Ethical considerations:

• Labeling: Risk of stigma for individuals who may never develop psychosis
• False positives: 70% of UHR individuals do NOT transition
• Medication risks: Side effects of antipsychotics in a population that may not need them
• Right to know: Informing individuals about risk without causing undue anxiety
• Balanced approach: Staging model respects both autonomy and prevention

Cross-reference: D1 Section 10.4

Q14. Describe newer antipsychotics. Write a note on cariprazine. [10 marks]

Exam Strategy: 5+5 split. Cover 4-5 newer agents, then deep dive on cariprazine.

Answer:

A. Newer Antipsychotics (5 marks)

Paradigm shifts:

• Lumateperone: Proves effective antipsychotic action at <65% D2 occupancy
• Cobenfy: Proves antipsychotic effect WITHOUT D2 blockade (muscarinic pathway)
• Cariprazine: D3 pathway for negative symptoms

B. Cariprazine, Detailed Note (5 marks)

Pharmacology:

• D3 receptor partial agonist with high preferential binding (D3 affinity 6-8x higher than D2)
• D2 partial agonist
• 5-HT1A partial agonist
• 5-HT2B antagonist
• Low affinity for H1, M1, alpha-1 (low metabolic/sedative/hypotensive risk)

Pharmacokinetics:

Clinical significance of long half-life:

• Missed doses have minimal impact on plasma levels (forgiveness factor)
• Effects and side effects persist for weeks after discontinuation
• Slower dose titration needed
• Takes 4-8 weeks to reach steady state

D3 Receptor and Negative Symptoms:

• D3 receptors concentrated in limbic and cortical areas (motivation, emotion, cognition)
• D3 partial agonism → enhancement of dopaminergic signaling in mesocortical pathway
• Nemeth et al. (2017), RCT: Cariprazine 4.5 mg vs Risperidone 4 mg for predominant negative symptoms over 26 weeks. Cariprazine showed statistically significant and clinically meaningful improvement on PANSS-FSNS (Factor Score for Negative Symptoms)
• First antipsychotic with RCT evidence specifically for primary negative symptoms

Indications:

1. Schizophrenia (positive and negative symptoms)
2. Bipolar I disorder, manic and mixed episodes
3. Bipolar I depression (monotherapy)

Side effects:

Advantages over other antipsychotics:

• Evidence for primary negative symptoms (unique)
• Low metabolic burden
• Long half-life improves adherence forgiveness
• Broad indication (schizophrenia + bipolar mania + bipolar depression)
• Favorable prolactin profile

Limitations:

• Akathisia can be dose-limiting
• Very long washout period
• Not available in all countries
• Cost
• EPS still possible at higher doses

Cross-reference: D1 Sections 8.3, 8.4

Q15. Negative symptoms of schizophrenia: describe and discuss management. [3+3+4 = 10 marks]

Exam Strategy: Overlap with Q1 and Q7. Use mark allocation to guide depth. This is more focused on negative symptoms specifically.

Answer:

A. Description of Negative Symptoms (3 marks)

[Content substantially overlaps with Q1 Section B. Key points:]

Negative symptoms represent a diminution or absence of normal functions. The concept was formalized by Crow (1980) as Type II symptoms and further developed by Andreasen (SANS, 1982).

Andreasen's five domains:

1. Affective flattening, reduced emotional expression (facial, vocal, gestural)
2. Alogia, poverty of speech/content
3. Avolition, loss of motivation and drive
4. Anhedonia/Asociality, inability to experience pleasure; social withdrawal
5. Attention impairment, difficulty sustaining attention

Newer conceptualization (Kirkpatrick): Two factors:

• Diminished expression (affective flattening + alogia)
• Avolition/apathy (avolition + anhedonia + asociality)

Deficit syndrome (Carpenter): Primary, enduring negative symptoms present in stable periods; ~15-25% of patients; associated with worse outcome.

B. Primary vs Secondary Distinction (3 marks)

Assessment approach: Rule out ALL secondary causes before labeling symptoms as primary.

Assessment tools: SANS, BNSS (Brief Negative Symptom Scale), CAINS (Clinical Assessment Interview for Negative Symptoms), PANSS negative subscale.

C. Management (4 marks)

Step 1: Address secondary negative symptoms

• Reduce antipsychotic dose if EPS/sedation contributing
• Switch to lower-EPS antipsychotic (aripiprazole, quetiapine)
• Treat depression (SSRI/SNRI/mirtazapine)
• Address substance use
• Improve environment (day programs, social contact)

Step 2: Pharmacological strategies for primary negative symptoms

Step 3: Psychosocial interventions

Emerging approaches:

• rTMS (repetitive transcranial magnetic stimulation), left DLPFC; modest evidence
• tDCS (transcranial direct current stimulation), emerging
• Oxytocin intranasal, social cognition; inconsistent results
• Glycine-site agonists (D-serine, sarcosine), glutamate modulation; modest

Cross-reference: D1 Section 2.2, Q1 above

Q16. Define compliance in psychiatry. Discuss causes of poor compliance. Discuss newer modalities for improving compliance in schizophrenia. [3+3+4 = 10 marks]

Exam Strategy: Define clearly (mention shift from compliance to adherence to concordance). Causes are systematic. Newer modalities = LAIs + digital tools.

Answer:

A. Definition (3 marks)

Compliance: The extent to which a patient's behavior (taking medication, following diet, lifestyle changes) coincides with medical advice. Term implies passive patient role.

Evolution of terminology:

Types of non-adherence:

• Complete non-adherence (stopping medication entirely)
• Partial adherence (reducing dose, irregular intake, drug holidays)
• Covert non-adherence (claiming to take medication but not doing so)

Rates in schizophrenia: 40-60% non-adherent within first year; up to 75% by 2 years.

Impact: Non-adherence is the strongest predictor of relapse in schizophrenia. Each relapse potentially causes further neurobiological damage and functional decline.

B. Causes of Poor Compliance (3 marks)

C. Newer Modalities for Improving Compliance (4 marks)

1. Long-Acting Injectable Antipsychotics (LAIs):

Benefits: Guaranteed delivery, transparent adherence, eliminates daily decision, reduces relapse by 20-30% vs oral.

2. Digital Adherence Technologies:

3. Psychoeducation and Motivational Approaches:

4. Simplified Regimens:

• Once-daily dosing (paliperidone ER, aripiprazole, lurasidone, cariprazine)
• Combination approaches reducing pill burden
• Extended-release formulations

5. Community-Based Approaches:

• ACT teams (Assertive Community Treatment): Bring medication to patient
• Community mental health workers (India: DMHP model)
• Directly Observed Therapy (DOT), adapted from TB model
• Home visits by community nurses

6. Side Effect Management:

• Proactive management of side effects BEFORE they cause non-adherence
• Switching to better-tolerated medication
• Addressing sexual dysfunction openly (often underreported)

Cross-reference: D1 Section 10.5

Q17. Discuss newer long-acting antipsychotics. Describe dosing and side effects of olanzapine pamoate. [10 marks]

Exam Strategy: 5+5 split. Cover all newer LAIs, then deep dive on olanzapine pamoate + PDSS.

Answer:

A. Newer Long-Acting Injectable Antipsychotics (5 marks)

Advantages of newer LAIs:

• Extended dosing intervals (up to 6 months with PP6M)
• SGA profile (less EPS than FGA LAIs)
• Transparent adherence
• Reduced relapse rates vs oral equivalent
• Some require no oral supplementation (PP1M, aripiprazole lauroxil with Initio)

Comparison of LAI properties:

B. Olanzapine Pamoate, Dosing and Side Effects (5 marks)

Formulation: Olanzapine pamoate monohydrate (salt of olanzapine and pamoic acid); slow dissolution from injection site over weeks.

Dosing:

• Maximum single injection: 405 mg
• Deep gluteal IM injection only (NOT deltoid, risk of too-rapid absorption)
• Use Z-track technique
• Reconstitute with provided diluent; use within 1 hour

Post-Injection Delirium/Sedation Syndrome (PDSS):

MANDATORY monitoring (REMS program):

• 3-hour observation at healthcare facility after EVERY injection
• Accompanied by healthcare provider or able to drive
• Monitor for sedation, confusion, altered consciousness
• If PDSS suspected: continuous monitoring in medical facility until fully recovered

Side effects (beyond PDSS):

Advantages:

• No oral overlap needed
• Effective for patients stabilized on oral olanzapine
• Transparent adherence

Disadvantages:

• PDSS risk requiring 3-hour monitoring (major logistical barrier)
• Gluteal only (no deltoid)
• High metabolic burden
• REMS registration required
• Limited prescribing due to monitoring requirements

Cross-reference: D1 Section 8.5

Q18. Discuss non-pharmacological treatments in schizophrenia. Write about the role of family therapy. [5+5 = 10 marks]

Exam Strategy: Overlap with Q9 and Q10. Keep non-pharmacological section broader (include ECT, brain stimulation). Family therapy section per Q10.

Answer:

A. Non-Pharmacological Treatments (5 marks)

1. Neuromodulation:

2. Psychological Interventions:

3. Vocational and Social:

4. Lifestyle:

B. Role of Family Therapy (5 marks)

[Content per Q10, key points:]

Rationale: High Expressed Emotion (critical comments, hostility, emotional over-involvement) → 50-65% relapse rate vs 15-25% in low EE households (Vaughn & Leff, 1976).

Models: Psychoeducational (Anderson/Falloon), Behavioral family management, Multiple family groups (McFarlane), Cognitive-behavioral family approaches.

Evidence: Cochrane meta-analysis: Reduces relapse by 20-50%; NNT ~7. Recommended by NICE for ALL patients in contact with family. Minimum 10 sessions over 3+ months.

Components:

1. Psychoeducation about the illness
2. Communication skills training (active listening, positive requests, constructive feedback)
3. Problem-solving techniques
4. Early warning signs identification and crisis planning
5. Emotional support for carers
6. Reducing self-blame and guilt in families

Benefits beyond relapse prevention:

• Improved medication adherence
• Reduced family burden and burnout
• Better patient social functioning
• Reduced hospitalization
• Cost-effective

Indian context considerations:

• Joint family system, opportunity and challenge
• Stigma may prevent families from engaging
• Cultural sensitivity needed
• Limited trained therapists; task-shifting to community health workers possible

Cross-reference: D1 Sections 10.1-10.2, Q9, Q10

Mnemonics & Memory Tricks

Mnemonic 1: Schneider's First Rank Symptoms

"ATPD", Auditory, Thought, Passivity, Delusional perception

Expand each:

Swipe to compare →

Alternate mnemonic for all 11 FRS: "ABCDE FITS MP"

• Auditory hallucinations (arguing)
• Broadcasting (thought)
• Commentary (running)
• Delusional perception
• Echo (thought)
• Feelings (made)
• Impulses (made)
• Thought insertion
• Somatic passivity
• Made actions
• Pullout = withdrawal (thought)

Mnemonic 2: Bleuler's 4 A's (Fundamental Symptoms)

"4 A's"

Remember: "Accessory symptoms (Hallucinations, Delusions) are NOT the 4 A's", Bleuler considered them secondary.

Mnemonic 3: Positive vs Negative Symptoms

Positive = "DHFB", Delusions, Hallucinations, FTD, Bizarre behavior

(Think: "D-Hab FB" = bad Facebook posts)

Negative = "5 A's of ANDREASEN":

1. Affective flattening
2. Alogia
3. Avolition
4. Anhedonia/Asociality
5. Attention impairment

Remember: Positive = too much of something; Negative = too little of something

Mnemonic 4: Good Prognostic Factors

"FAMILY LAMP"

Mnemonic 5: Poor Prognostic Factors

"MINUS HELP"

Mnemonic 6: Catatonia Features (Bush-Francis Key Items)

"SOME GRIPS WEEN"

Extra features to add: Catalepsy, Ambitendency, Verbigeration, Mannerisms, Mitgehen, Gegenhalten

Mnemonic 7: Clozapine Side Effects

"CLOZAPINE SWAMPS"

Mnemonic 8: Clozapine Monitoring Schedule

"18 - 52 - LIFE"

Stopping rules, "3-1.5 STOP":

• WBC <3000 or ANC <1.500 → STOP clozapine
• ANC <500 (agranulocytosis) → STOP permanently, never rechallenge

Mnemonic 9: FGA vs SGA Comparison

"FGA = D2 Dominant, SGA = Serotonin-Dopamine Duo"

Mnemonic 10: D2 Occupancy Therapeutic Window

"65-80 SWEET SPOT"

Mnemonic 11: Metabolic Syndrome Criteria (ATP III)

"BIG WAIST"

Need ANY 3 of 5 criteria to diagnose.

Mnemonic 12: TRS Definition Criteria

"TWO-SIX-SIX"

Plus: At least 1 trial must be an SGA. Adherence must be confirmed. Pseudo-resistance excluded.

Mnemonic 13: Andreasen's Remission Criteria

"DUH-CM-BSL", 8 PANSS items, all must be ≤ mild for ≥ 6 months

Duration: ≥ 6 months at mild or below.

Mnemonic 14: Dopamine Pathways

"MINT", 4 pathways

Mnemonic 15: EPS Timeline

"Days-Weeks-Months-Years = DAPA-TARD"

Mnemonic 16: Clozapine Drug Interactions

"SMOKE, COFFEE, FLUVOX raise or lower"

Key rule: "CYP1A2 is Clozapine's Achilles heel"

Mnemonic 17: Metabolic Risk Ranking of Antipsychotics

"COQR-AZL" (pronounced "cocker-azle")

From highest to lowest metabolic risk:

• Clozapine = Olanzapine (highest)
• Quetiapine = Risperidone (moderate)
• Aripiprazole = Ziprasidone = Lurasidone (lowest)

Mnemonic 18: Newer Antipsychotic Mechanisms

"C-L-B-C: The New Four"

Mnemonic 19: Expressed Emotion Components

"CHO", Criticism, Hostility, Over-involvement

High EE = 50-65% relapse. Low EE = 15-25% relapse.

Mnemonic 20: LAI Dosing Intervals

"1-2-3-6 Palmitate" for Paliperidone:

Other intervals to know:

• Risperdal Consta: Every 2 weeks (the only biweekly SGA LAI)
• Aripiprazole (Abilify Maintena): Monthly (14-day oral overlap)
• Olanzapine pamoate: Every 2-4 weeks (3-hour watch for PDSS)

High-Yield Comparisons

Table 1: ICD-11 vs DSM-5: Schizophrenia Diagnosis

Swipe to compare →

Key exam point: The biggest practical difference is DURATION, ICD-11 diagnoses schizophrenia 5 months earlier. What ICD-11 calls schizophrenia at 1 month, DSM-5 would call schizophreniform disorder until 6 months.

Table 2: Positive vs Negative Symptoms

Table 3: FGA vs SGA Antipsychotics

Table 4: Good vs Poor Prognostic Factors

Table 5: Schneider's First Rank vs Second Rank Symptoms

Table 6: Catatonia Features with Bush-Francis Scoring

Bush-Francis Catatonia Rating Scale (BFCRS), 23 items, rated 0-3

Screening: First 14 items form the screening tool. Score ≥2 = positive screen for catatonia.

Lorazepam challenge: 1-2 mg IV → observe 5-15 min → 50%+ improvement = positive.

Table 7: Antipsychotic Side Effects by Receptor

Clinical application: When switching antipsychotics to manage side effects, choose a drug with a different receptor profile targeting the problematic receptor.

Table 8: Clozapine vs Other SGAs

Table 9: Newer Antipsychotics

PYQ Frequency Analysis

Executive Summary

Schizophrenia is the single highest-yield topic in all of psychiatry exams. With 49+ mentions across 28 PG exams sessions, it appears in virtually every exam, often multiple times across different papers. You WILL get at least one schizophrenia question. Probably two.

Topic-Level Frequency

Swipe to compare →

Must-Prepare PYQ Templates

1. "Describe positive and negative symptoms. Management of negative symptoms.", perennial
2. "Define TRS. Management protocol (pharmacological + psychological).", perennial
3. "Clozapine, initiation, monitoring, side effects.", perennial
4. "Course and outcome of schizophrenia." / "Prognostic factors.", perennial
5. "First rank symptoms. Current status.", classic
6. "Atypical antipsychotics, why atypical? Side effects.", perennial
7. "Psychosocial treatment / rehabilitation in schizophrenia.", perennial
8. "ICD-11 vs DSM-5 diagnosis of schizophrenia.", emerging
9. "Prodromal symptoms. Early intervention.", emerging
10. "Newer antipsychotics. Cariprazine.", emerging hot topic

Analysis based on PG exams Dec 2011, Jun 2025 + PG exams 2013-2022.

Quick Review

Vignette 1: First Episode Psychosis

Case: A 21-year-old male engineering student is brought by his parents with a 6-month history of declining academic performance, social withdrawal, and suspiciousness. Over the past 2 months, he has been talking to himself, laughing inappropriately, and locking himself in his room claiming that his classmates are plotting against him. He believes his thoughts are being broadcast through his laptop. He has no prior psychiatric history. There is no history of substance use. A paternal uncle was diagnosed with schizophrenia.

Q1. What is the most likely diagnosis? Justify with ICD-11 and DSM-5 criteria.

Answer:

Diagnosis: Schizophrenia, first episode, currently in acute episode.

ICD-11 justification:

• Duration >1 month of symptoms (2 months of frank psychosis)
• Core symptoms present: Persecutory delusions (classmates plotting), Thought broadcasting (FRS), Auditory hallucinations (talking to himself = likely responding to voices)
• Prodromal features for 4 months prior (social withdrawal, functional decline)

DSM-5 justification:

• Criterion A: ≥2 symptoms present, delusions, hallucinations, negative symptoms (withdrawal). At least 1 is delusion/hallucination
• Criterion B: Social/occupational dysfunction (academic decline)
• Criterion C: Total duration >6 months (4 months prodrome + 2 months active = 6 months)
• Criterion D: No mood disorder to account for symptoms
• Criterion E: No substance use

Note: Thought broadcasting is an FRS but does not receive special diagnostic weight in either DSM-5 or ICD-11.

Q2. What are the differential diagnoses?

Answer:

1. Schizophreniform disorder, if DSM-5 duration criterion not met (<6 months); here 6-month criterion is borderline
2. Brief psychotic disorder, duration <1 month; excluded here
3. Substance-induced psychotic disorder, cannabis/stimulant use; excluded by history but urine drug screen warranted
4. Bipolar disorder with psychotic features, assess for mood episodes; no prominent mood symptoms here
5. Delusional disorder, but hallucinations and disorganization point toward schizophrenia
6. Organic psychosis, rule out with physical examination, basic labs, neuroimaging if indicated (first episode, seizures, etc.)
7. Schizotypal personality disorder, subthreshold, chronic; the acute psychotic presentation exceeds this

Q3. Outline the management plan.

Answer:

Immediate:

• Comprehensive assessment: MSE, physical examination, collateral from family
• Investigations: CBC, RFT, LFT, TFT, fasting glucose, lipid profile, urine drug screen, ECG
• Neuroimaging: MRI brain (first episode, to rule out organic causes)
• Risk assessment: Suicidality, harm to others, self-care capacity

Pharmacological:

• Start SGA: Risperidone 2 mg/day or Aripiprazole 10-15 mg/day (first episode patients respond at lower doses)
• Low starting dose (first-episode patients are medication-naive and more sensitive)
• Target D2 occupancy 65-80%
• If agitation: Short-term benzodiazepine (lorazepam 1-2 mg)
• Avoid polypharmacy at this stage

Psychosocial:

• Psychoeducation: Patient and family, nature of illness, importance of treatment, prognosis
• Family intervention: Assess expressed emotion, educate about early warning signs
• Supported education: Facilitate return to studies if possible
• CBTp: Once acute symptoms settle
• Relapse prevention planning

Follow-up:

• Weekly initially, then fortnightly
• Metabolic monitoring from baseline
• Adequate trial: 4-6 weeks at therapeutic dose before considering switch
• Minimum 1-2 years of treatment after first episode (some guidelines suggest longer)

Vignette 2: Treatment-Resistant Schizophrenia

Case: A 34-year-old male with a 12-year history of schizophrenia presents with persistent auditory hallucinations (commanding voices) and persecutory delusions despite treatment with risperidone 8 mg/day for 10 weeks followed by olanzapine 20 mg/day for 12 weeks. Medication adherence has been confirmed by family supervision and plasma level monitoring. He is unemployed, socially isolated, and his self-care is poor. He has been hospitalized 5 times in the past 8 years.

Q1. Does this patient meet criteria for treatment-resistant schizophrenia (TRS)? Define TRS.

Answer:

Yes, this patient meets TRS criteria.

TRRIP Working Group Definition (Howes et al., 2017):

1. ≥2 adequate antipsychotic trials, Yes (risperidone 8 mg, olanzapine 20 mg, both above 600 mg CPZ equivalents)
2. Adequate dose, Yes (risperidone 8 mg ≈ 800 CPZ; olanzapine 20 mg ≈ 600 CPZ)
3. Adequate duration, Yes (10 weeks and 12 weeks, both >6 weeks)
4. Adherence confirmed, Yes (family supervision + plasma levels)
5. At least 1 SGA trial, Yes (both are SGAs)
6. Persistent moderate-severe positive symptoms, Yes (commanding voices, persecutory delusions)
7. Significant functional impairment, Yes (unemployed, isolated, poor self-care)

Pseudo-resistance has been excluded (adherence confirmed, adequate doses/durations, no substance use mentioned).

Q2. What is the next step in management?

Answer:

Clozapine trial, the only evidence-based treatment for TRS.

Pre-initiation:

• Baseline: CBC with differential (WBC >3500, ANC >2000), metabolic panel, LFT, ECG, troponin, CRP, weight/BMI/waist
• Stop/cross-taper olanzapine over 1-2 weeks
• Register with clozapine monitoring service
• Informed consent (patient + family)

Initiation:

• Day 1: 12.5 mg at night
• Increase by 25-50 mg/day over first week
• Increase by 50-100 mg/week from week 2
• Target: 300-450 mg/day
• Check plasma level at steady state: target >350 ng/mL

Monitoring:

• WBC/ANC: weekly for 18 weeks → biweekly for 34 weeks → monthly
• Metabolic: weight monthly; glucose, lipids at 3 months then annually
• Cardiac: troponin/CRP weekly for first 4 weeks (myocarditis screening)
• Bowel function: every visit

Q3. If clozapine alone is insufficient after an adequate trial, what augmentation strategies are available?

Answer:

An adequate clozapine trial = plasma level >350 ng/mL for ≥8 weeks.

Swipe to compare →

Algorithm: Clozapine monotherapy → Clozapine + amisulpride → Clozapine + ECT → Clozapine + lamotrigine. Throughout: psychosocial interventions (CBTp, family, supported employment, ACT team).

Vignette 3: Catatonia

Case: A 30-year-old female with a known diagnosis of schizophrenia is brought to the emergency department after being found standing motionless in her room for 18 hours. On examination, she is mute, staring into space, with increased tone in all limbs. When the examiner positions her arm in an elevated position, she maintains it for over 2 minutes. She is not eating or drinking. Temperature is 38.2 C, pulse 118/min, BP 150/95 mmHg. CK is elevated at 1200 IU/L.

Q1. What is the diagnosis? What features of catatonia are described?

Answer:

Diagnosis: Catatonia associated with schizophrenia. Given the fever, autonomic instability, and elevated CK, this is malignant catatonia, a life-threatening emergency.

Catatonic features identified:

1. Stupor, motionless for 18 hours, not relating to environment
2. Mutism, no verbal response
3. Staring, fixed gaze
4. Rigidity, increased tone in all limbs
5. Waxy flexibility/Catalepsy, maintains externally imposed arm position for >2 minutes
6. Withdrawal, not eating or drinking

Malignant features: Fever (38.2 C), tachycardia (118), hypertension (150/95), elevated CK (1200), suggestive of autonomic instability and muscle breakdown.

Q2. What is your differential diagnosis?

Answer:

1. Malignant catatonia, most likely given the presentation
2. Neuroleptic Malignant Syndrome (NMS), must rule out; is she on antipsychotics? NMS presents with similar features (rigidity, fever, autonomic instability, elevated CK). Lead-pipe rigidity in NMS vs waxy flexibility in catatonia, though overlap exists
3. Anti-NMDA receptor encephalitis, young female, psychiatric symptoms, autonomic instability; check anti-NMDA receptor antibodies
4. Serotonin syndrome, if on serotonergic medications; clonus, hyperreflexia, diarrhea differentiate
5. Encephalitis (viral), LP, MRI, EEG needed
6. Metabolic derangement, DKA, hepatic encephalopathy
7. Status epilepticus (non-convulsive), EEG needed

Q3. Outline emergency management.

Answer:

Immediate (first hour):

• ABCs, IV access, monitoring (cardiac, SpO2, temperature)
• IV fluids for dehydration and rhabdomyolysis prevention
• Stop ALL antipsychotics (if NMS cannot be excluded)
• Investigations: CBC, CMP, CK, LFT, RFT, TFT, troponin, urine myoglobin, blood cultures, urine drug screen, LP (if infection suspected), MRI brain, EEG, anti-NMDA receptor antibodies

Lorazepam challenge test:

• IV lorazepam 1-2 mg
• Observe for 5-15 minutes
• Positive response (improvement in rigidity, movement, speech) confirms catatonia and guides treatment
• If positive: Continue lorazepam 8-24 mg/day in divided IV doses

If lorazepam insufficient or malignant features persist:

• Emergency bilateral ECT, daily or alternate day
• ECT is the definitive treatment for malignant catatonia (80-90% response)
• Typically 6-10 sessions

Supportive care:

• DVT prophylaxis (immobility)
• Pressure sore prevention
• Nutritional support (NG tube if needed)
• Temperature management
• Monitor CK, renal function (rhabdomyolysis → AKI)

If NMS confirmed: Dantrolene 1-2.5 mg/kg IV + bromocriptine 2.5 mg TDS + supportive care

Vignette 4: Comorbid Substance Use Disorder

Case: A 26-year-old male was diagnosed with schizophrenia at age 22. He has been smoking cannabis daily since age 17. Over the past year, his psychotic symptoms have worsened despite being on olanzapine 15 mg/day. He frequently misses appointments, his family reports that he sometimes skips medication, and his urine drug screen is positive for cannabis and amphetamines. He was recently involved in a physical altercation in his neighborhood.

Q1. What is the diagnosis? How does substance use impact schizophrenia?

Answer:

Diagnosis: Schizophrenia with comorbid substance use disorder (cannabis use disorder + amphetamine use disorder).

Impact of substance use on schizophrenia:

Q2. What are the differential diagnoses to consider?

Answer:

1. Substance-induced psychotic disorder, cannabis and amphetamine use can independently cause psychosis; however, persistent psychosis between periods of use + premorbid onset + 4-year history suggests primary schizophrenia with comorbid SUD
2. Pseudo-resistance, apparent treatment failure due to non-adherence + active substance use (NOT true TRS)
3. Bipolar disorder with psychotic features + SUD, amphetamine use may mimic mania
4. Antisocial personality traits, aggression + substance use; comorbid personality assessment needed

Q3. Outline a management plan.

Answer:

Immediate:

• Comprehensive assessment: substance use history (type, quantity, frequency, route, last use), psychiatric symptoms during periods of abstinence (if any), risk assessment (violence, self-harm)
• Urine drug screen confirmation and monitoring

Pharmacological:

• Address non-adherence FIRST, consider LAI (paliperidone palmitate or aripiprazole monohydrate)
• Avoid olanzapine if non-adherent (oral only); switch to LAI
• If continued psychosis despite abstinence + LAI: escalate as per TRS pathway
• Clozapine consideration if true TRS after establishing abstinence and adherence
• Clozapine may specifically reduce substance use in schizophrenia patients (some evidence)

Substance use treatment (integrated dual-diagnosis approach):

• Motivational interviewing for substance use
• Psychoeducation about cannabis/amphetamine effects on psychosis
• Harm reduction if abstinence not immediately achievable
• Consider referral to dual-diagnosis program
• No specific pharmacotherapy for cannabis use disorder; for amphetamine use disorder, no approved pharmacotherapy but behavioral approaches effective

Psychosocial:

• Integrated dual-diagnosis treatment (IDDT) model
• ACT team if available (for complex, high-service-use patients)
• Family intervention (high EE likely)
• Anger management
• Social skills training
• Supported employment when stable

Vignette 5: Elderly-Onset Psychosis

Case: A 62-year-old retired schoolteacher presents with a 3-month history of believing that her neighbors are stealing her belongings and poisoning her food. She hears voices of the neighbors planning against her. She lives alone after her husband died 2 years ago. She has well-controlled hypertension and type 2 diabetes. There is no prior psychiatric history. Cognitive screening (MMSE) is 27/30. MRI brain shows mild age-related atrophy.

Q1. What is the most likely diagnosis? What differentials should be considered in late-onset psychosis?

Answer:

Most likely diagnosis: Late-onset schizophrenia (sometimes called "late paraphrenia" historically, though this term is no longer in standard use). Alternatively, very late-onset schizophrenia-like psychosis (onset >60 years) as per the international consensus (Howard et al., 2000).

Differentials in late-onset psychosis:

Q2. How does late-onset schizophrenia differ from early-onset?

Answer:

Q3. How would you manage this patient?

Answer:

Assessment:

• Detailed cognitive assessment (neuropsychological battery, not just MMSE)
• Sensory assessment (hearing, vision, sensory deprivation can precipitate/maintain paranoia)
• Full medical workup: TFT, B12, folate, RPR/VDRL, HIV, CRP, CBC, LFT, RFT, HbA1c
• Review all medications for psychotogenic potential
• Assess social isolation, bereavement, loneliness

Pharmacological:

• Start LOW, go SLOW, elderly are more sensitive to antipsychotics
• Risperidone 0.5-2 mg/day or Aripiprazole 5-10 mg/day (lower dose range)
• Avoid olanzapine (metabolic burden on existing diabetes)
• Avoid quetiapine at high doses (orthostatic hypotension fall risk)
• Monitor for metabolic effects (already has DM and HTN)
• QTc monitoring (cardiac risk)
• Fall risk assessment

Psychosocial:

• Address social isolation (day center, social group, befriending service)
• Bereavement support/grief counseling if unresolved
• Hearing aid if hearing impairment detected
• Family/neighbor engagement for support
• CBTp adapted for elderly
• Home-based care if possible

Considerations:

• Cerebrovascular risk: antipsychotics in elderly increase stroke risk (black box warning for dementia, relevant consideration here)
• Falls risk: any sedating or hypotension-causing medication is dangerous
• Follow up cognition: if MMSE declines, consider prodromal dementia with psychosis

Vignette 6: Negative-Symptom-Dominant Presentation

Case: A 28-year-old male is brought by his mother who reports that over the past 3 years, he has become progressively apathetic, stopped bathing, quit his job, has no friends, watches TV all day, and shows no emotional response even when family members are distressed. He rarely speaks beyond monosyllables. He had one psychotic episode at age 23 with persecutory delusions and auditory hallucinations, which resolved with treatment. He is currently on risperidone 4 mg/day. There are no current delusions or hallucinations.

Q1. What is the primary clinical issue? How would you classify these negative symptoms?

Answer:

Primary issue: Predominant negative symptoms in the residual phase of schizophrenia.

Negative symptoms present:

• Avolition (quit job, apathetic, watches TV all day)
• Affective flattening (no emotional response)
• Alogia (monosyllabic speech)
• Asociality (no friends)
• Poor self-care (stopped bathing)

Classification, Primary vs Secondary:

Must systematically assess whether these are primary (intrinsic to illness) or secondary (treatable cause):

If all secondary causes excluded: Deficit syndrome (Carpenter), primary, enduring negative symptoms present during and between episodes. Prevalence: 15-25% of schizophrenia. Worst prognosis subgroup.

Q2. What changes would you make to medication?

Answer:

Step 1: Address potential secondary causes

• Reduce risperidone to 2 mg (minimum effective dose for relapse prevention), may reduce EPS-mediated negative symptoms
• OR switch to aripiprazole 10-15 mg (D2 partial agonist, less EPS, less prolactin, potentially activating)

Step 2: If primary negative symptoms persist after addressing secondary causes

• Cariprazine 3-6 mg/day, strongest RCT evidence for predominant negative symptoms (D3-preferring partial agonist)
• OR Amisulpride 50-200 mg/day, low-dose preferential presynaptic D2/D3 blockade
• Consider add-on antidepressant (mirtazapine 15-30 mg or fluoxetine 20 mg) for motivational/anhedonic overlap

Step 3: Monitor response over 8-12 weeks

• Use standardized assessment (BNSS or SANS) at baseline and follow-up

Q3. What psychosocial interventions would you recommend?

Answer:

1. Behavioral activation (adapted from CBTp), activity scheduling, graded task assignment, goal-setting
2. Social skills training, role-playing social interactions, conversation skills
3. Cognitive remediation, computer-based exercises for attention and executive function (best when combined with vocational rehab)
4. Supported employment (IPS), structured activity and purpose; shown to improve motivation
5. Art/music therapy, non-verbal engagement, emotional expression
6. Physical exercise program, 150 min/week; evidence for cognitive improvement + motivation
7. Family intervention, educate family about negative symptoms (they are NOT laziness); reduce critical comments; prevent over-accommodation
8. Environmental enrichment, day program, social club, structured daily routine

Vignette 7: Metabolic Complications

Case: A 38-year-old female with a 10-year history of schizophrenia has been stable on olanzapine 20 mg/day for the past 4 years with good symptom control. She now weighs 98 kg (BMI 37), her waist circumference is 104 cm, fasting glucose is 142 mg/dL, HbA1c is 7.2%, triglycerides are 280 mg/dL, HDL is 38 mg/dL, and BP is 138/88 mmHg. She is concerned about her weight but is fearful of changing medication as she remembers her psychotic relapses.

Q1. What is the diagnosis? How many criteria for metabolic syndrome does she meet?

Answer:

Diagnosis: Metabolic syndrome secondary to olanzapine use, with new-onset type 2 diabetes mellitus.

ATP III criteria assessment:

She meets ALL 5 of 5 criteria, severe metabolic syndrome.

Additionally: HbA1c 7.2% confirms Type 2 Diabetes Mellitus (>6.5%).

Q2. What are the management options?

Answer:

Approach 1: Switch antipsychotic (preferred if feasible)

• Switch from olanzapine to a metabolically safer antipsychotic
• Options: Aripiprazole (best metabolic profile), Lurasidone (weight-neutral), Ziprasidone (weight-neutral), Cariprazine (low metabolic risk)
• Cross-titration strategy: Gradually increase new drug while slowly decreasing olanzapine over 4-6 weeks
• Close monitoring for psychotic relapse during switch
• Discuss risks vs benefits with patient, her fear of relapse is valid and must be addressed through shared decision-making

Approach 2: Add metformin (if switching not possible/patient refuses)

• Metformin 500 mg BD → 1000 mg BD
• Evidence: Reduces weight by 2-3 kg, improves insulin sensitivity
• Also directly addresses diabetes

Approach 3: Add aripiprazole to olanzapine

• Aripiprazole 5-10 mg/day added to olanzapine may improve metabolic parameters
• Evidence: Moderate; meta-analysis supports modest benefit

Metabolic management regardless of approach:

• Diabetes: Metformin +/- other antidiabetics; endocrine referral
• Dyslipidemia: Statin (atorvastatin); lifestyle modification
• Hypertension: Lifestyle first; if persistent, antihypertensive
• Lifestyle: Structured diet counseling, exercise program (150 min/week), smoking cessation if applicable
• Monitoring: Weight monthly, fasting glucose/HbA1c quarterly, lipids quarterly until stable

Q3. If you decide to switch to aripiprazole, how would you manage the transition?

Answer:

Cross-titration protocol:

Key considerations:

• Monitor for insomnia/akathisia (common with aripiprazole, especially activating early on)
• Monitor for psychotic relapse (weekly check-ins during transition)
• Olanzapine withdrawal symptoms: Insomnia, nausea, diaphoresis (cholinergic rebound), taper slowly
• If psychotic symptoms re-emerge during switch: Slow down taper, consider partial switch (lower olanzapine + aripiprazole)
• Family psychoeducation about the switch and early warning signs
• Reassure patient: The switch is being done carefully for her long-term health

Vignette 8: Clozapine Management

Case: A 40-year-old male with treatment-resistant schizophrenia has been on clozapine 450 mg/day for 2 years with good control of positive symptoms (plasma level: 420 ng/mL). He smokes 20 cigarettes/day. He is admitted to hospital for an elective hernia surgery where smoking is not permitted. On post-operative day 2, he becomes excessively drowsy, drooling profusely, has a tonic-clonic seizure, and his blood pressure is 85/55 mmHg.

Q1. What is the most likely cause of this acute deterioration?

Answer:

Diagnosis: Clozapine toxicity secondary to abrupt smoking cessation.

Mechanism:

• Tobacco smoke (specifically polycyclic aromatic hydrocarbons, NOT nicotine) induces CYP1A2
• CYP1A2 is the primary enzyme metabolizing clozapine
• Abrupt cessation of smoking removes CYP1A2 induction
• Within 2-4 days, clozapine levels can DOUBLE
• His therapeutic level of 420 ng/mL may have risen to 700-800+ ng/mL
• Dose-dependent toxicity: seizures (>600 ng/mL risk increases significantly), sedation, hypotension, sialorrhea

Evidence supporting this diagnosis:

• Temporal relationship: Admitted → stopped smoking → day 2 symptoms
• Symptoms consistent with clozapine toxicity: excessive sedation, seizure (dose-dependent), hypotension, profuse drooling
• Known smoker (20/day) with CYP1A2 induction now removed

Q2. How should this be managed acutely?

Answer:

Immediate:

1. Seizure management: Lorazepam 2-4 mg IV; protect airway; do NOT give phenytoin (may interact)
2. Hypotension: IV fluids; avoid vasopressors initially; position patient flat
3. Urgent clozapine level: Confirm toxicity (expect >600 ng/mL)
4. Hold clozapine until seizure resolved and levels obtained
5. Monitor: Continuous cardiac monitoring, pulse oximetry, neurological observations

Once stable:

1. Reduce clozapine dose by 30-50%: From 450 mg → 225-300 mg/day
2. Recheck plasma level after dose reduction and once at new steady state (5-7 days)
3. Target level: 350-600 ng/mL
4. Consider valproate for seizure prophylaxis if maintaining dose >300 mg (dose-dependent seizure risk)
5. Sialorrhea management: Glycopyrrolate or hyoscine while profuse

Prevention for future:

• If patient resumes smoking after discharge: Will need dose RE-INCREASE (as CYP1A2 re-induced)
• Educate patient and surgical team about clozapine-smoking interaction
• NRT (nicotine replacement therapy) does NOT prevent clozapine level changes, it is the smoke, not the nicotine
• Document prominently in medical records

Q3. What other drug interactions with clozapine should clinicians be aware of?

Answer:

Vignette 9: Depot/LAI Considerations

Case: A 29-year-old male with schizophrenia has had 4 psychotic relapses in 3 years, each preceded by medication non-adherence confirmed by undetectable plasma levels. He currently responds well to oral paliperidone 9 mg/day when he takes it consistently. His family is exhausted from trying to supervise his medication. He has poor insight and frequently says he does not need medication because "there is nothing wrong" with him.

Q1. What is the main barrier to treatment success? What intervention would you recommend?

Answer:

Main barrier: Medication non-adherence driven by poor insight (anosognosia).

Anosognosia is present in ~50% of schizophrenia patients and is NOT simply "denial", it is a neurobiological deficit (associated with right frontal lobe dysfunction).

Recommended intervention: Switch to Long-Acting Injectable (LAI) antipsychotic, specifically Paliperidone Palmitate 1-monthly (PP1M), since he is already stable on oral paliperidone.

Rationale for LAI:

• Eliminates daily adherence decisions
• Transparent adherence (clinician/family knows when injection was given)
• Reduces relapse by 20-30% compared to oral equivalent
• Steady plasma levels (fewer peaks and troughs)
• Reduces caregiver burden
• Evidence that early LAI use (within first 2 years) improves long-term outcomes

Q2. Describe the initiation protocol for paliperidone palmitate.

Answer:

PP1M (1-monthly) initiation:

• No oral supplementation needed (loading doses provide therapeutic levels)
• Can discontinue oral paliperidone after Day 1 injection
• Adjust maintenance dose based on response and tolerability
• If previous oral dose was 6 mg → maintenance 117 mg; if 9 mg → 156 mg; if 12 mg → 234 mg

Once stable on PP1M for ≥4 months, can transition to PP3M:

• PP3M dose = 3.5x the PP1M dose
• Example: PP1M 156 mg → PP3M 546 mg every 3 months

Eventually, PP6M:

• After adequate period on PP1M/PP3M
• PP6M 1092 mg every 6 months

Q3. How would you address the patient's poor insight?

Answer:

Pharmacological: LAI itself removes the daily insight-dependent decision.

Psychoeducation:

• Avoid direct confrontation about "being ill" (increases resistance)
• Motivational interviewing approach: explore discrepancy between patient's goals and current situation
• Reframe medication as "helping you stay out of hospital" rather than "because you are sick"
• Use relapse history: "Every time you stopped, you ended up in hospital, what was that like?"

Psychosocial:

• CBTp with specific focus on illness beliefs and health beliefs
• LEAP approach (Amador): Listen, Empathize, Agree (on shared goals), Partner
• Peer support from others with lived experience
• Family education about anosognosia (it's NOT willful denial)

Legal considerations (if insight remains absent and repeated relapses):

• Community Treatment Order (CTO) where legally available
• Supported decision-making
• Crisis plan and advance directives (when patient has partial insight)

Vignette 10: Forensic Considerations

Case: A 35-year-old male with paranoid schizophrenia was found standing over his neighbor's body holding a knife. He claims the neighbor was an alien who was going to abduct him. He has a 10-year history of schizophrenia with multiple admissions. His last psychiatric visit was 6 months ago; he stopped olanzapine 4 months ago. Urine drug screen is positive for methamphetamine.

Q1. What psychiatric and forensic issues need to be addressed?

Answer:

Psychiatric issues:

1. Acute psychotic episode with persecutory and bizarre delusions (neighbor = alien, abduction)
2. Medication non-adherence (stopped olanzapine 4 months ago)
3. Comorbid substance use (methamphetamine, worsens psychosis, increases violence risk)
4. Risk assessment: Has committed serious violence; ongoing risk while psychotic
5. Capacity assessment: Likely lacks capacity for treatment decisions currently

Forensic issues:

1. Criminal responsibility: Was the act committed under influence of psychotic symptoms? Assess for McNaughtan rules applicability (did he know the nature and quality of his act? Did he know it was wrong?)
2. Mental state at the time of offense: Detailed assessment needed; collateral from witnesses; timeline of symptoms
3. Fitness to stand trial: Can he understand proceedings, instruct a lawyer?
4. Section/involuntary admission: Required for treatment (lacks insight, danger to others)
5. Indian legal framework: Section 84 IPC (now BNS Section 22), Act of a person of unsound mind; Mental Healthcare Act 2017, provisions for supported admission
6. Substance intoxication vs psychosis: Methamphetamine may have precipitated/worsened psychosis but underlying schizophrenia is the primary disorder

Q2. How would you assess his mental state at the time of the alleged offense?

Answer:

Retrospective assessment:

• Detailed psychiatric interview (once stable enough)
• Timeline: When did he stop medication? When did symptoms worsen? What was his mental state in days/hours before the event?
• Nature of delusions: Were they commanding? Did he believe he was acting in self-defense against the "alien"?
• Substance use: When was the last use? What quantity? Does methamphetamine independently explain the behavior?
• Previous violence: Any pattern of violence during psychotic episodes?
• Collateral: Family, neighbors, previous psychiatrist, hospital records
• Physical evidence: Crime scene details, toxicology at time of arrest

Assessment of McNaughtan criteria (Indian law, Section 84 IPC / BNS Section 22):

1. Did he know the NATURE of the act? (Did he know he was stabbing a person?), He may have known the physical act but believed the "person" was an alien
2. Did he know it was WRONG?, If he genuinely believed he was defending against an alien abduction, he may not have known it was wrong

Tools: HCR-20 (violence risk), PCL-R (if personality features), detailed MSE documentation

Q3. How would you manage this patient going forward?

Answer:

Acute management:

• Involuntary admission under Mental Healthcare Act 2017
• Restart antipsychotic, consider clozapine (TRS likely given multiple admissions + violence + non-adherence)
• Address methamphetamine: Detoxification, psychoeducation, relapse prevention
• 24/7 observation initially (continued violence risk)
• Physical examination and investigations

Medium-term:

• Stabilize on medication (clozapine if TRS; otherwise LAI to prevent future non-adherence)
• LAI strongly indicated: Paliperidone palmitate or zuclopenthixol decanoate
• Substance use treatment (integrated dual-diagnosis)
• Violence risk management (structured professional judgment, HCR-20)
• Fitness to stand trial assessment once stable
• Prepare psychiatric report for court

Long-term:

• Forensic community mental health follow-up
• Mandatory LAI (possibly via CTO)
• ACT team if available
• Substance use monitoring
• Family intervention
• Violence risk monitoring
• Supervised housing if no family support

Vignette 11: OCD Comorbidity with Schizophrenia

Case: A 32-year-old female with schizophrenia has been on clozapine 400 mg/day for 2 years with good control of psychotic symptoms. Over the past 8 months, she has developed repetitive handwashing (30+ times/day, hands are cracked and bleeding), checking rituals (locks, gas stove, 20+ minutes each), and distressing intrusive thoughts about contamination. She recognizes these as excessive. Y-BOCS score is 28 (severe). She had no OCD symptoms before starting clozapine.

Q1. What is the likely diagnosis and its relationship to clozapine?

Answer:

Diagnosis: Clozapine-induced obsessive-compulsive symptoms (OCS) / OCD.

Relationship to clozapine:

• Prevalence: Clozapine-associated OCS occurs in 20-30% of patients; full OCD criteria in 5-10%
• Mechanism: 5-HT2A and 5-HT2C blockade by clozapine → serotonergic dysregulation → OC symptoms
• Dose-dependent: Higher clozapine doses associated with higher risk
• Temporal relationship: Symptoms developed after clozapine initiation; absent before
• She has good insight (recognizes symptoms as excessive), typical of OCS/OCD

Distinguishing from psychotic symptoms:

• OCD: Ego-dystonic, recognized as excessive, causes anxiety, resisted
• Delusions/psychotic rituals: Ego-syntonic, not resisted, no insight
• Her symptoms are clearly OCD (distressing, recognized as excessive)

Q2. How would you manage the OCD symptoms?

Answer:

Step 1: Do NOT stop clozapine, she is treatment-resistant and clozapine has controlled her psychosis. Stopping would risk psychotic relapse.

Step 2: Pharmacological options:

Step 3: If adding fluvoxamine:

• Start fluvoxamine 25 mg/day
• Simultaneously reduce clozapine from 400 mg to 200 mg
• Monitor clozapine plasma level at 1-2 weeks
• Titrate fluvoxamine to 100-150 mg based on OCD response
• Target clozapine level: 350-600 ng/mL (may be achieved at lower clozapine dose due to interaction)

Step 4: CBT for OCD

• Exposure and Response Prevention (ERP), gold standard
• May need modification for patients with schizophrenia (simpler hierarchies, slower pace, repeated practice)

Q3. What clozapine dose adjustment is needed if fluvoxamine is started?

Answer:

Critical interaction: Fluvoxamine is the most potent CYP1A2 inhibitor among SSRIs. Adding it to clozapine without dose adjustment can cause clozapine toxicity (seizures, sedation, hypotension, agranulocytosis risk).

Protocol:

1. Before starting fluvoxamine: Check baseline clozapine level
2. Reduce clozapine dose by 50-75% (e.g., 400 mg → 100-200 mg)
3. Start fluvoxamine at low dose (25 mg)
4. Recheck clozapine level after 1-2 weeks
5. Target clozapine level 350-600 ng/mL
6. Titrate fluvoxamine slowly to effective dose for OCD (100-200 mg)
7. Repeat clozapine level after each fluvoxamine dose change
8. Monitor for toxicity signs: excessive sedation, seizures, hypotension, tachycardia

Note: This interaction can also be used therapeutically, in patients who are rapid metabolizers or smokers with low clozapine levels, adding low-dose fluvoxamine can deliberately boost clozapine levels ("fluvoxamine augmentation strategy").

Vignette 12: First-Episode Psychosis with Catatonic Features

Case: An 18-year-old female college student is brought to emergency by her roommate. Over 2 weeks, she became increasingly withdrawn, stopped attending classes, and was heard muttering to herself. Today, she was found lying in bed, unresponsive, maintaining her arms in odd positions. She is not speaking, not eating, and alternates between complete immobility and sudden bursts of purposeless agitation. No prior psychiatric history. Drug screen negative. No significant medical history.

Q1. What is the clinical presentation and likely diagnosis?

Answer:

Clinical presentation: First episode of psychosis with prominent catatonic features (retarded type with episodes of excited catatonia).

Catatonic features:

• Stupor (unresponsive, lying in bed)
• Mutism (not speaking)
• Posturing (maintaining arms in odd positions)
• Withdrawal (not eating)
• Excitement (sudden purposeless agitation)
• Possible alternation between retarded and excited catatonia

Psychotic features (preceding catatonia):

• Auditory hallucinations (muttering to herself)
• Social withdrawal (prodromal/active phase)
• Functional decline

Likely diagnosis: Schizophrenia, first episode with catatonia specifier (DSM-5) OR Schizophrenia with psychomotor disturbance qualifier (ICD-11).

Differentials:

1. Bipolar disorder with catatonia, assess for any mood episode history
2. Anti-NMDA receptor encephalitis, young female, psychiatric symptoms + catatonia (must rule out!)
3. Autoimmune encephalitis, antibody panel
4. Medical catatonia, drug screen negative but consider other causes
5. Brief psychotic disorder with catatonia

Q2. What investigations are essential in this case?

Answer:

Priority investigations:

Q3. How would you manage her?

Answer:

Immediate:

1. Admit; continuous monitoring
2. IV fluids, nutrition (NG tube if prolonged mutism/refusal)
3. DVT prophylaxis
4. Pressure sore prevention

Catatonia treatment:

1. Lorazepam challenge: 2 mg IV → observe 15 minutes
2. If positive: Lorazepam 8-24 mg/day IV in divided doses
3. If no response to lorazepam within 48-72 hours or if malignant features develop: ECT, bilateral, daily or alternate day

Once catatonia resolves and organic causes excluded:

• Start antipsychotic cautiously (catatonia can worsen with high-potency antipsychotics)
• Avoid haloperidol (can worsen catatonia)
• Use low-dose SGA: Olanzapine 5-10 mg or quetiapine 200-300 mg (lower D2 binding preferred)
• Continue benzodiazepine initially alongside antipsychotic

If anti-NMDA receptor encephalitis confirmed:

• First-line: IV methylprednisolone + IVIG or plasmapheresis
• Second-line: Rituximab, cyclophosphamide
• Tumor resection if teratoma found
• Antipsychotics for symptom management (low-dose, preferably SGA)

Vignette 13: Schizophrenia with Pregnancy

Case: A 30-year-old female with stable paranoid schizophrenia on risperidone 4 mg/day discovers she is 8 weeks pregnant. This is a planned pregnancy discussed with her psychiatrist 6 months ago. She has had 2 psychotic episodes, the last being 3 years ago. She is currently symptom-free and functioning well. She is anxious about medication effects on the baby.

Q1. What are the key considerations regarding antipsychotic use in pregnancy?

Answer:

Risk-benefit analysis:

Key facts about antipsychotics in pregnancy:

• No antipsychotic is FDA category A (none proven safe)
• Most data on chlorpromazine, haloperidol (decades of use); SGAs, growing data but less
• No consistent pattern of major malformations with any antipsychotic
• Olanzapine and clozapine: highest risk of gestational diabetes
• Risperidone: Relatively well-studied; generally considered acceptable in pregnancy
• General principle: The risk of untreated psychosis in pregnancy almost always outweighs the risk of medication

Q2. What would you advise regarding her current medication?

Answer:

Recommendation: Continue risperidone at the lowest effective dose.

Rationale:

• She has had 2 previous episodes (relapse risk is high)
• Currently stable, do NOT change medication during pregnancy (avoid switches that add risk)
• Risperidone has a reasonable safety profile in pregnancy (Huybrechts et al., 2016)
• Dose reduction: Consider lowering to 3 mg if possible (minimum effective dose)
• Avoid adding/switching medications (each new drug adds unknown teratogenic risk)

Monitoring plan:

Q3. What about breastfeeding?

Answer:

Risperidone and breastfeeding:

• Risperidone and its active metabolite (paliperidone) are excreted in breast milk
• Relative infant dose: ~4-5% (generally <10% considered acceptable)
• Paliperidone may be preferred over risperidone (lower milk-to-plasma ratio)
• Most guidelines: Breastfeeding can be considered with monitoring

General principles:

• Benefits of breastfeeding (bonding, nutrition, immunity) vs drug exposure
• Shared decision-making with mother
• If breastfeeding: Monitor infant for sedation, feeding difficulties, developmental milestones
• Avoid polypharmacy during breastfeeding
• Clozapine: Generally NOT recommended during breastfeeding (agranulocytosis risk to infant; high milk transfer)
• Olanzapine: Limited transfer; considered compatible by many guidelines

Vignette 14: Tardive Dyskinesia

Case: A 55-year-old male with chronic schizophrenia has been on haloperidol 15 mg/day for 20 years with good symptom control. Over the past year, his family noticed repetitive lip-smacking, tongue protrusion, and jaw movements. He also makes purposeless hand movements. He is unaware of these movements. An attempt to reduce haloperidol led to worsening of these movements and re-emergence of psychotic symptoms.

Q1. What is the diagnosis? Describe the features.

Answer:

Diagnosis: Tardive Dyskinesia (TD) secondary to chronic haloperidol use.

Features described:

• Orofacial movements: lip-smacking, tongue protrusion, jaw movements (classic TD triad)
• Choreiform hand movements
• Involuntary, purposeless, repetitive
• Patient unaware (common in TD, impaired awareness)
• Worsened on dose reduction (unmasking phenomenon)

TD characteristics:

• Onset: After months-years of antipsychotic use (typically >3 months in adults, >1 month in elderly)
• Risk: ~5% per year with FGAs; cumulative risk 25-30% after 5 years; lower with SGAs (~1%/year)
• Irreversible in 50-70% of cases
• Risk factors: Older age, female sex, longer duration/higher dose of FGA, diabetes, mood disorder, early EPS
• Assessment: Abnormal Involuntary Movement Scale (AIMS), standard monitoring tool
• Pathophysiology: D2 receptor supersensitivity from chronic blockade

Q2. How would you manage the tardive dyskinesia?

Answer:

Step 1: Switch from haloperidol (FGA) to SGA

• Cross-taper to quetiapine (least D2 blockade among common SGAs) or clozapine (only antipsychotic that can treat TD)
• Clozapine is the preferred switch if psychotic symptoms are difficult to control (he relapsed on dose reduction)
• Slow cross-taper to minimize psychotic relapse

Step 2: VMAT2 inhibitors (FDA-approved for TD)

• Both FDA-approved specifically for tardive dyskinesia
• VMAT2 inhibition → decreased dopamine packaging into vesicles → reduced dopaminergic transmission
• Valbenazine generally preferred (once daily, less depression risk)

Step 3: Adjunctive

• Benzodiazepines (clonazepam 0.5-2 mg/day), may provide modest benefit
• Vitamin E, weak evidence; may slow progression (not reverse)
• Ginkgo biloba, some RCT evidence in Chinese populations

Q3. What preventive measures should have been taken?

Answer:

1. Use SGAs preferentially (lower TD risk than FGAs)
2. Lowest effective dose of any antipsychotic
3. Regular AIMS screening: Every 6 months for FGAs; annually for SGAs; every 3 months in high-risk groups (elderly, female)
4. Early detection: Educate patient and family about early signs
5. Avoid anticholinergics long-term (may mask early TD; increase risk)
6. Consider LAI SGAs for non-adherent patients (more predictable dosing)
7. Document baseline AIMS before starting any antipsychotic
8. If early TD detected: Immediate switch to lower-risk antipsychotic (clozapine, quetiapine); start VMAT2 inhibitor

Vignette 15: Ultra-High Risk / Prodromal Phase

Case: A 17-year-old male high school student is referred by his school counselor. Over 6 months, his grades have dropped from A's to D's, he has stopped playing basketball, withdrawn from friends, and sleeps excessively. He tells the counselor he sometimes feels like people are watching him, hears faint whispers that he cannot make out, and has become convinced that certain numbers have special meaning for him. His mother has schizophrenia. He does not meet criteria for a psychotic disorder as symptoms are below threshold for frank psychosis.

Q1. What clinical category does this patient fall under? What are the criteria?

Answer:

Category: At-Risk Mental State (ARMS) / Ultra-High Risk (UHR) for psychosis.

He meets TWO UHR criteria:

1. Attenuated Psychotic Symptoms (APS):

• Suspiciousness (feels people watching him), sub-threshold persecutory ideation
• Perceptual disturbances (faint whispers), sub-threshold hallucinations
• Magical thinking (numbers have special meaning), sub-threshold delusional ideation
• Present for >1 week in past year

2. Trait + State risk:

• Genetic risk: First-degree relative with schizophrenia (mother)
• Functional decline: Grades dropped from A to D (>30% drop in GAF equivalent)

Assessment tools:

• CAARMS (Comprehensive Assessment of At-Risk Mental States), structured interview
• SIPS/SOPS (Structured Interview for Prodromal Syndromes)

Conversion risk: ~30% will develop frank psychosis within 3 years. This means 70% will NOT, critical for management decisions.

Q2. What are the differential diagnoses?

Answer:

Q3. How would you manage this patient?

Answer:

Assessment:

• Comprehensive psychiatric evaluation (CAARMS/SIPS)
• Cognitive assessment (baseline, important for monitoring)
• Urine drug screen (cannabis, stimulants)
• Physical examination, basic blood work, TFT
• Family history details (mother's illness course)
• Risk assessment (suicidality, self-harm)
• GAF/SOFAS for functional monitoring

Management (staged approach):

Stage 1, Low-risk interventions (start here):

• CBT (NICE-recommended for ARMS): 14-26 sessions targeting distressing beliefs, anxiety, social withdrawal, functional recovery
• Psychoeducation: Age-appropriate, non-alarmist explanation of risk; involve family
• Stress management: Sleep hygiene, study skills, social engagement
• Substance use: If cannabis used, motivational interviewing for cessation
• Family support: Mother's illness means he has witnessed psychosis; address his fears and genetic concerns
• School engagement: Liaise with school counselor for academic support

Stage 2, If symptoms worsen:

• Consider low-dose antipsychotic ONLY if transitioning to frank psychosis
• Omega-3 fatty acids (EPA + DHA 1-2g/day), low risk, some supportive data
• Antidepressant if depressive symptoms prominent

Monitoring:

• Monthly initially; assess for progression to psychosis
• Repeat CAARMS/SIPS at 3-6 month intervals
• Cognitive monitoring annually
• If frank psychosis develops: Immediate referral to early intervention in psychosis (EIP) service; initiate treatment as per first-episode protocol (low-dose SGA)

Key ethical consideration: Communicate risk proportionately. 70% chance he will NOT develop psychosis. Avoid labeling. Use terms like "stress vulnerability" rather than "pre-schizophrenia." Involve him in all decisions (age-appropriate shared decision-making).